Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | CASP6 | P55212 | 1/20 | 0.64 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 9/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370534 | 0.94 | TDP1 (0.56) | TDP1POLBAPEX1CASP6CTDSP1 | |
| SCHEMBL5375674 | 0.83 | NR1H4 (0.55) | TDP1POLBAPEX1CASP6CTDSP1 | |
| SCHEMBL6140258 | 0.81 | TDP1 (0.69) | TDP1POLBAPEX1CASP6CTDSP1 | |
| SCHEMBL6140946 | 0.80 | TDP1 (0.71) | TDP1POLBAPEX1CASP6CTDSP1 | |
| SCHEMBL6140264 | 0.78 | CASP6 (0.69) | TDP1POLBAPEX1CASP6CTDSP1 | |
| SCHEMBL32690181 | 0.78 | TDP1 (1.00) | TDP1POLBAPEX1CASP6CTDSP1 | |
| SCHEMBL1928415 | 0.78 | ALDH1A1 (0.64) | HTTMAPTLMNAMEN1KMT2A | |
| SCHEMBL6140454 | 0.78 | POLB (0.69) | TDP1POLBAPEX1CASP6CTDSP1 | |
| SCHEMBL16592564 | 0.78 | RECQL (0.62) | CASP6HTTMAPTLMNAMEN1 | |
| SCHEMBL15725834 | 0.78 | ALDH1A1 (0.64) | TDP1HTTMAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182260-A1 | Process for the preparation of cyclic imides in the presence of polyphosphoric acid | MERCK PATENT GMBH (DE) | 2005-08-18 | — | — | US | disclosed |
| EP-1506173-A1 | METHOD FOR PRODUCING CYCLIC IMIDES IN THE PRESENCE OF POLYPHOSPHORIC ACID | MERCK PATENT GmbH (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097600-A1 | METHOD FOR PRODUCING CYCLIC IMIDES IN THE PRESENCE OF POLYPHOSPHORIC ACID | MERCK PATENT GMBH (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182260-A1 | Process for the preparation of cyclic imides in the presence of polyphosphoric acid | PPIP5K2, ITPA, IPMK | TDP1 2026/4885POLB 1147/4885APEX1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.